TrialPath
Recruiting

French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls

NCT07881016 · Fondation FondaMental
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Cohorte française Longitudinale et Multimodale de Patients Atteints de Troubles Majeurs de l'Humeur, de Troubles Psychotiques, de Troubles du Spectre de l'Autisme et de témoins
About this study
Background and rationale Severe psychiatric disorders such as major mood disorders, psychotic disorders and autism spectrum disorders are clinically, genetically and biologically heterogeneous, which limits the efficacy of current treatments. Precision psychiatry requires deep and objective phenotyping of large samples to identify homogeneous subgroups that share common clinical and biological features and may benefit from targeted prevention and treatment strategies. Based on the literature and international consensus, social withdrawal and anhedonia are two particularly robust transdiagnostic dimensions with an underlying biological hypothesis, validated French measurement tools, existing translational models, and recognised relevance for patients. French Minds is part of the French national research programme PEPR PROPSY (Precision Psychiatry), funded by the French government under France 2030. It extends pre-existing French psychiatric cohorts to build a multimodal database of more than 10,000 deeply phenotyped patients. Study design National, multicentre, prospective, longitudinal cohort study (French "Jardé" law, category 1 interventional research not involving a health product). Patients are recruited in French Minds centres, i.e., the FondaMental Foundation expert centres and the First Episode Psychosis (PEP) / RHU PsyCare centres. Healthy volunteers are recruited through advertising and pre-screened by telephone, then assessed with the MINI interview at inclusion. Study procedures * Visit 0 (inclusion): eligibility check, informed consent, sociodemographic and medical history, self-questionnaires; routine biological check-up prescribed for patients. * Visit 1 (within 8 weeks of V0, one day): fasting blood sample for research (genotyping, whole-genome sequencing, DNA methylation, RNA and microRNA sequencing, metabolomics and lipidomics, proteomics, inflammatory and immune markers, autoantibodies, immune cell subpopulations), metabolic and anthropometric measures, neuropsychological assessment (CANTAB, WAIS-IV subtests, CVLT, theory of mind tasks, verbal fluency, attention), motor strength, minor neurological signs, clinician-rated scales (BPRS, C-SSRS, treatment response and resistance, life events, neurodevelopmental history, autoimmune psychosis criteria), and self-questionnaires. * Visit 2 (within 6 weeks of V1): 3T brain MRI (structural and functional sequences, harmonised across sites), approximately one hour. * Visit 3 (12 to 14 months after V1, one day): same assessments as V1, plus course of illness since V1 (episodes, hospitalisations, care use, treatment history). * Visit 4 (within 6 weeks of V3): 3T brain MRI identical to V2. * Optional stool collection at home at V0 and V3 for gut microbiome (metagenomic) analysis, subject to specific consent. * Between visits (over one year): digital phenotyping using a study-provided smartphone with the Kanopsy app (validated self-questionnaires on anhedonia, sleep, loneliness, pain, anxiety and depression, repeated over one year) and a connected watch for passive collection of activity, sleep and heart rate variability. A safety alert redirects participants to the French national suicide prevention line (3114) when scores indicate clinical concern. * Environmental exposure is estimated from residential history and housing characteristics. Linkage with the French National Health Data System (SNDS) is planned to study long-term care trajectories, subject to specific regulatory authorisations (CESREES, CNIL). Biological samples are stored in a dedicated biobank (Hôpitaux Universitaires Henri Mondor, AP-HP). Genomic analyses are performed at the CNRGH (CEA) and MRI acquisition harmonisation, centralisation and quality control are handled by the CATI national neuroimaging platform. Statistical analysis Approximately 500 patients per diagnostic group (2,500 patients) and 500 healthy volunteers will be included, allowing estimation of subgroup proportions (expected 20-50% per disorder) with 5% precision (alpha 5%), accounting for 20% loss to follow-up or refusal. Analyses will combine clustering methods, multivariate regression, analysis of variance, growth and survival models for longitudinal data, and exploratory data-mining / machine-learning approaches. Missing data will be handled by multiple imputation and multiple testing will be controlled using the false discovery rate (FDR). Expected benefits There is no direct individual benefit; the expected benefit is collective, through improved understanding of prognostic factors and biological mechanisms in severe psychiatric disorders, with the potential to support the development of new, more personalised therapeutic strategies.
Eligibility criteria
Inclusion Criteria: Patients: * Aged 15 to 60 years at inclusion * Already assessed in a FondaMental expert centre or a First Episode Psychosis (PEP) / RHU PsyCare centre * Signed informed consent (and consent of parents/legal guardians for minors, or of the curator for adults under curatorship) * Confirmed DSM-5 diagnosis at inclusion of at least one of the following: * Non-specific first-episode psychosis\* * Schizophrenia * Bipolar disorder * Major depressive disorder (recurrent or treatment-resistant) * Autism spectrum disorder without intellectual disability * Clinical condition compatible with clinical, biological and imaging assessments * Affiliated with or beneficiary of a social security scheme * Women of childbearing potential: negative blood or urine pregnancy test at inclusion * Agrees to be informed of any abnormality detected on MRI \*Non-specific first-episode psychosis: patients aged 35 or younger, with significant functional impairment (SOFAS), presenting at least two concurrent psychotic symptoms (e.g., hallucinations, delusions, disorganisation) or a first onset of a psychotic disorder (ICD-10 F20-F29) or mood disorder with psychotic features (ICD-10 F30-F39), with the episode lasting more than 7 days and first frank psychotic symptoms having appeared less than 2 years ago. Healthy volunteers (matched to patients by sex and 10-year age group): * Aged 18 to 60 years at inclusion * Signed informed consent * No personal or first-degree family history, in the past 5 years, of: non-specific first-episode psychosis, schizophrenia, bipolar disorder, recurrent or treatment-resistant depressive disorder, or autism spectrum disorder without intellectual disability * No current prescription of antidepressant, antipsychotic, mood stabiliser or psychostimulant for a characterised disorder * No use of antidepressant, antipsychotic, mood stabiliser or psychostimulant in the past 5 years * Condition compatible with clinical, biological and imaging assessments * Affiliated with or beneficiary of a social security scheme * Women of childbearing potential: negative blood or urine pregnancy test at inclusion * Agrees to be informed of any abnormality detected on MRI Exclusion Criteria: Patients: * Unstabilised somatic or psychiatric condition * Contraindication to MRI * Emergency situation, inability to give consent, or under judicial protection (sauvegarde de justice) * Pregnant or breastfeeding women * Refusal to be informed of any abnormality detected on MRI Healthy volunteers: * Psychiatric disorder in the past 5 years (screened with the MINI interview) * Unstabilised somatic condition * Contraindication to MRI * Inability to give consent * Pregnant or breastfeeding women * Refusal to be informed of any abnormality detected on MRI
Study design
Enrollment target: 3000 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult
Timeline
Starts: 2026-06-11
Estimated completion: 2031-06
Last updated: 2026-10-19
Interventions
Procedure: 3T Brain MRIProcedure: Biological SamplingOther: Clinical, Cognitive and Digital Assessments
Primary outcomes
  • • Proportion of participants in each transdiagnostic subgroup defined by social withdrawal and anhedonia. (Baseline (Visit 1))
Sponsor
Fondation FondaMental · other
With: Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE), Assistance Publique - Hôpitaux de Paris, AGENCE NATIONALE DE RECHERCHE
Contacts & investigators
ContactImene Ben Mohamed · contact · imene.benmohamed@fondation-fondamental.org · +33 7 58 25 17 49
InvestigatorMarion Leboyer · study_director, Institut National de la Santé Et de la Recherche Médicale, France
All locations (17)
CHU de BesançonActive Not Recruiting
Besançon, France
Centre Hospitalier Charles PerrensRecruiting
Bordeaux, France
CHU de BrestRecruiting
Brest, France
Centre Hospitalier Le VinatierRecruiting
Bron, France
CHU Clermont FerrandActive Not Recruiting
Clermont-Ferrand, France
CHU Clermont-FerrandRecruiting
Clermont-Ferrand, France
Hopital Louis MourierRecruiting
Colombes, France
Hopital Albert ChenevierRecruiting
Créteil, France
CHU Grenoble Alpes - Hôpital NordRecruiting
Grenoble, France
CHU de LilleActive Not Recruiting
Lille, France
Hopital Sainte-MargueriteRecruiting
Marseille, France
CHU de MontpellierRecruiting
Montpellier, France
GHU Sainte-AnneActive Not Recruiting
Paris, France
Hopital LariboisièreNot Yet Recruiting
Paris, France
CHU de Saint-ÉtienneRecruiting
Saint-Etienne, France
CHU de ToulouseActive Not Recruiting
Toulouse, France
CHU de ToursActive Not Recruiting
Tours, France